Assembled from the company's filings and exchange data as of today. Download PDF renders this page on the server; the narrative sections arrive with the Nexa composer.
Dossier · GENOMIC VALLEY BIOTECH LIMITED · 29 October 2026Page 1 of 3
Company Dossier
MarketPing Research · factual · no rating expressed
GENOMIC VALLEY BIOTECH LIMITED
BSE: 539206
BSE: 539206
Healthcare › Healthcare › Pharmaceuticals & Biotechnology › Biotechnology
GENOMIC VALLEY BIOTECH LIMITED
StateQ1 FY27 filed
Last close · 28 Oct 2026₹43.63
Market cap₹0.0k cr
TTM P/E · P/B · EV/EBITDA363.6 · 3.39 · 395.3
GENOMIC VALLEY BIOTECH LIMITED is a Pharmaceuticals & Biotechnology company. The annual-report business brief for this company has not been generated yet; the numbers below are as filed.
What a broker report prints here — the analyst's thesis. This dossier prints the filed record instead; the narrative read of the latest results, the guidance ledger and the earnings-call summary are the composer's sections (INSTITUTIONAL-PLAN.md M3) and are not yet produced.
Exhibit 1: Financial summary, FY22–FY26 (all audited; no estimate years)
| ₹ crore · standalone | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Revenue | 0 | 3 | 0 | 1 | 0 |
| EBITDA (ex other income) | 0 | 1 | 0 | 0 | 0 |
| margin % | 58.2 | 22.6 | 9.0 | 52.1 | 16.3 |
| Owners' profit | (0) | 1 | 0 | 0 | 0 |
| EPS, as reported (₹) | (0.03) | 2.12 | 0.05 | 1.17 | 0.10 |
| ROE % · ROCE % | (0.3) · 1.1 | 18.4 · 18.4 | 0.4 · 0.4 | 9.1 · 11.3 | 0.8 · 1.0 |
| Debt / equity (x) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash from operations | (2) | (1) | (0) | 0 | (0) |
| Capex | 0 | 0 | 0 | (0) | 0 |
Source: SEBI results XBRL as filed with BSE/NSE; EBITDA excludes other income.
Every figure is a filed number or a ratio over filed numbers · No rating, target or fair value is expressed · Disclosures on the last pagemarketping.in
Dossier · GENOMIC VALLEY BIOTECH LIMITED · 29 October 2026Page 2 of 3
Exhibit 2: Quarterly performance, last 8 quarters
| ₹ crore | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit before tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net profit | 0 | 0 | (0) | 0 | 0 | 0 | (0) | 0 |
| EPS (₹) | 0.48 | 0.51 | 0.27 | 0.08 | 0.01 | 0.03 | 0.03 | 0.05 |
Source: quarterly results as filed; the balance sheet is filed half-yearly and is not repeated here.
Exhibit 3: Peers — basic industry group, by market cap
| Company | M.cap ₹ cr | P/E | P/B | EV/EBITDA | ROE % | ROCE % | Rev CAGR 5y % | EBITDA m. % |
|---|---|---|---|---|---|---|---|---|
| ANTHEM BIOSCIENCES LTD | 46,905 | 121.2 | 15.42 | 48.4 | 19.5 | 26.6 | — | 42.0 |
| ADVANCED ENZYME TECH LTD | 2,932 | 17.7 | 1.74 | 10.3 | 10.3 | 13.4 | 8.2 | 33.7 |
| CCME GLOBAL LIMITED | 144 | 93.9 | 3.61 | — | (1.8) | (1.8) | — | — |
| VIVO BIO TECH LTD. | 31 | 3.2 | 0.33 | 4.5 | (1.8) | 3.2 | 0.6 | 31.5 |
| Shree Ganesh Biotech (India) L | 18 | 23.0 | 0.29 | — | 0.6 | 0.8 | — | (7.0) |
| GENOMIC VALLEY BIOTECH LIMITED ◆ | 13 | 363.6 | 3.39 | — | 0.8 | 1.0 | — | 40.5 |
Source: exchange data and filed statements via the screener; multiples at current prices.
Exhibit 4: Where the company sits in its group
| Metric | Company | Group median | Rank | Better than |
|---|---|---|---|---|
| P/E (TTM) | 363.6 | 30.8 | 161 of 164 | 2% |
| P/B | 3.4 | 3.1 | 97 of 169 | 43% |
| ROCE | 1.0 | 10.7 | 152 of 189 | 20% |
| ROE | 0.8 | 9.5 | 141 of 172 | 18% |
| Debt / Equity | 0.0 | 0.1 | 1 of 172 | 78% |
| EBITDA margin | 40.5 | 17.7 | 10 of 170 | 95% |
| Revenue growth | (57.8) | 15.3 | 159 of 166 | 4% |
| Profit growth | (40.9) | 30.0 | 130 of 164 | 21% |
| Market cap | 13 | 798 | 178 of 187 | 5% |
Source: MarketPing peer ranks; a rank is a measurement, not a view.
Every figure is a filed number or a ratio over filed numbers · No rating, target or fair value is expressed · Disclosures on the last pagemarketping.in
Dossier · GENOMIC VALLEY BIOTECH LIMITED · 29 October 2026Page 3 of 3
Exhibit 5: Filings of the last 90 days, with the measured price reaction
| Date · filing | Category | Importance | Next day % | 5-day % |
|---|---|---|---|---|
| 27 Oct 2026 · Open offer for up to 794,170 GVBL equity shares | strategic transactions | high | — | — |
| 21 Oct 2026 · Board meeting on Oct 30 to consider Q2 and H1 FY26 financial results | results | low | — | — |
| 20 Oct 2026 · Promoters sell 46.06% stake; acquirers gain control and must make open offer | strategic transactions | critical | — | — |
| 19 Oct 2026 · Open Offer by Pankaj Grover and Abhisek Gupta for 26 percent of Genomic Valley Biotech | strategic transactions | high | — | — |
| 10 Oct 2026 · RTA certificate for Q2 FY27 dematerialisation filed with BSE | compliance | minimal | — | — |
| 28 Sept 2026 · Please find enclosed herewith intimation for closure of trading window. | compliance | minimal | — | — |
| 31 Aug 2026 · AGM deadline extended by 3 months to December 31, 2026 | board shareholder meetings | medium | — | — |
| 17 Aug 2026 · GVBL Q1 FY27 results show Rs 101.16 lakh loss, EPS at negative 1.09 | compliance | minimal | — | — |
| 14 Aug 2026 · GVBL Q1 FY26-27 results: revenue drops 58% YoY but margins improve | results | high | — | — |
| 14 Aug 2026 · Board approves Q1 FY27 results; revenue declines over 57 percent YoY | results | high | — | — |
Source: exchange announcements; each reaction is measured from the close before the filing. Next day = the close one session after the reaction day (the first session that could trade the filing).
How to read this document
| Where a broker report shows | This document shows | Why |
|---|---|---|
| A rating (BUY / ADD / REDUCE / SELL) | A state: the latest filed quarter and the measured reactions | an event is a fact; a rating is an opinion that requires SEBI RA registration |
| A target price and upside | The current price and the multiples against the group | a target is a forecast; a multiple is a measurement |
| Estimate years marked E | More audited years; no estimates | MarketPing publishes no forecasts — your own model lives on the Models page |
Sources, method and disclosures
This document is a statistical summary of publicly filed information and market data, prepared by software from primary sources: SEBI results XBRL filed with BSE and NSE, LODR disclosures, shareholding patterns, exchange price data. It contains no research recommendation, no price target and no opinion on the merits of any security, and is not a research report within the meaning of the SEBI (Research Analysts) Regulations, 2014, Regulation 2(1)(w)(vii). Financial statements are as filed (consolidated where the company files consolidated results). Ratios are computed over filed lines. Where a figure is unavailable the table shows a dash rather than an estimate. The business brief is written by MarketPing's reader from the annual report and checked against it; no figure in a table was generated by a model. Nothing here constitutes investment advice, an offer or a solicitation; readers should consult a SEBI-registered adviser before acting. MarketPing is not a SEBI-registered intermediary.
Every figure is a filed number or a ratio over filed numbers · No rating, target or fair value is expressed · Disclosures on the last pagemarketping.in